159 related articles for article (PubMed ID: 8637241)
1. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
[TBL] [Abstract][Full Text] [Related]
2. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
3. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
7. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
8. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
9. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
10. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
11. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.
Xu Y; Scheinberg DA
Clin Cancer Res; 1995 Oct; 1(10):1179-87. PubMed ID: 9815910
[TBL] [Abstract][Full Text] [Related]
12. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
14. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
16. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
[TBL] [Abstract][Full Text] [Related]
17. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Bernstein ID
Leukemia; 2000 Mar; 14(3):474-5. PubMed ID: 10720144
[TBL] [Abstract][Full Text] [Related]
19. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
20. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]